Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 21;13:2169. doi: 10.1038/s41467-022-29857-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a AUCs of 5 chemotherapeutic agents in 39 exocrine PDPCOs (38 CAS-DACs and 1 CAS-IPMN). With respect to each chemotherapeutic agent, the 39 PDPCOs were divided equally into sensitive (blue, AUC lowest 1st-13th), intermediate (yellow, AUC lowest 14th–26th) and resistant (red, AUC lowest 27th–39th) groups. The gray dot indicated CAS-DAC-14. b Diagram of the clinical analysis workflow. c Kaplan-Meier survival analysis showing the recurrence-free survival outcomes of the patients corresponding to the 39 PDPCOs. P value is determined by using log-rank test. Based on the consistency between the clinical adjuvant chemotherapy regimen and chemosensitivity of the matched organoid, three groups were identified: sensitive (n = 10), intermediate (n = 13) and resistant (n = 8). d Representative radiation examination of both the surgical area and liver in the sensitive group (CAS-DAC-24, CE-CT), intermediate group (CAS-DAC-20, CE-MRI), and resistant group (CAS-DAC-22, CE-MRI) at the time of diagnosis and six months post-surgery. Yellow arrow, primary tumor; Blue arrow, hepatic cyst; Red arrow, metastasis. e Drug test of ODX-18 with GEM (n=6), using Vehicle as a control (n=6). Data are presented as mean values + SEM. Statistical Significance was computed by two-sided unpaired t test. Source data are provided as a Source Data file. f Drug test of ODX-20 with GEM (n = 6) and 5-FU (n = 6), using Vehicle as a control (n = 6). Data are presented as mean values + SEM. Statistical Significance was computed by two-sided unpaired t test. Source data are provided as a Source Data file. g Drug test of ODX-36 with GEM (n = 6), 5-FU (n = 6) and PTX (n = 6), using Vehicle as a control (n=6). Data are presented as mean values + SEM. Statistical Significance was computed by two-sided unpaired t test. Source data are provided as a Source Data file. Statistical analysis, ns P ≥ 0.05,*P < 0.05, **P < 0.01, ***P < 0.001. PDPCO, patient-derived pancreatic cancer organoid; AUC, area under curve; GEM, gemcitabine; 5-FU, 5-fluorouracil; PTX, paclitaxel; OXA, oxaliplatin; IRI, irinotecan; CE-CT: contrast-enhanced computed tomography; CE-MRI: contrast-enhanced magnetic resonance imaging.